Conduit Pharmaceuticals (CDT) provides an R&D update on the development progress of pipeline assets AZD1656, AZD5658, and AZD5904. The ...

Conduit Pharmaceuticals advances its pipeline with key progress in preclinical lupus studies for AZD5658, Phase IIa trial design for AZD1656, ...

We recently compiled a list of the 10 Best Micro Cap Stocks to Buy Now. In this article, we are going to take a look at where ...

Conduit Pharmaceuticals Inc. announced that it presented a compliance plan to Nasdaq regarding its listing rules, specifically seeking an extension to comply with minimum bid price and market ...

Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) was the target of a significant increase in short interest during the month of February.As of February 15th, there was short interest ...

NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 06, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) announces that, on ...

and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the ...

Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), today announced the restructuring of a portion of its financial obligations, enhancing its balance sheet and liquidity.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Conduit Pharmaceuticals and Charles River Laboratories have announced a partnership to evaluate AZD1656, a glucokinase activator, in a preclinical model of systemic lupus erythematosus (SLE). This ...

In this article, we are going to take a look at where Conduit Pharmaceuticals Inc. (NASDAQ:CDT) stands against the other micro cap stocks. Just as we overlook loose change, micro-cap stocks are ...

and CAMBRIDGE, United Kingdom, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), is pleased to announce the completion of the initial ...